4//SEC Filing
Cloonan Michael 4
Accession 0001704336-25-000008
CIK 0002036042other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 5:39 PM ET
Size
25.0 KB
Accession
0001704336-25-000008
Insider Transaction Report
Form 4
Cloonan Michael
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-21−22,895→ 86,674 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (22,895 underlying) - Sale
Common Stock
2025-10-21$34.44/sh−13,324$458,879→ 547,343 total - Sale
Common Stock
2025-10-21$35.63/sh−30,049$1,070,646→ 547,343 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-21−30,049→ 109,569 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (30,049 underlying) - Exercise/Conversion
Common Stock
2025-10-21$6.11/sh+33,532$204,881→ 580,875 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-21−33,532→ 53,142 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (33,532 underlying) - Sale
Common Stock
2025-10-21$36.60/sh−22,895$837,957→ 547,343 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-21−13,324→ 139,618 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (13,324 underlying) - Exercise/Conversion
Common Stock
2025-10-21$6.11/sh+13,324$81,410→ 560,667 total - Exercise/Conversion
Common Stock
2025-10-21$6.11/sh+30,049$183,599→ 577,392 total - Exercise/Conversion
Common Stock
2025-10-21$6.11/sh+22,895$139,888→ 570,238 total - Sale
Common Stock
2025-10-21$37.31/sh−33,532$1,251,079→ 547,343 total
Footnotes (6)
- [F1]This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.00 to $37.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F6]The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
Related Parties
1- filerCIK 0001704336
Filing Metadata
- Form type
- 4
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 5:39 PM ET
- Size
- 25.0 KB